Bullish DRCT post argues a short squeeze is set up by tight float, heavy short interest, and a Nasdaq compliance extension, targeting $25.
Unpriced research observations (excluded from Calls and Returns):
DRCT — LONG The author claims DRCT is a bullish short-squeeze play: a tight float with heavily concentrated short interest (Fintel reports 389.44% of float) and low days-to-cover should force covering on sustained buy volume. A Nasdaq bid-price compliance extension through Jan. 30, 2026 is cited as removing an overhang, alongside operational updates to improve revenue mix and reduce losses, with a $25 price target if a squeeze triggers layered covering and a rapid sentiment flip. The main stated risk is that DRCT remains a microcap with low liquidity, so downside is real if volume fails or sentiment turns. resolved_entity_name_mismatch
Bullish structured target: $25 price target assuming a short squeeze event triggers layered cover, retail entry, and rapid sentiment flip.